Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 1998

View Archived Issues

Dimethaid Research: nine-month highlights

Roche describes new agents for neurodegenerative disorders

ABT-431, an improved therapeutic option for PD

MOR-14 exhibits protective potential against ischemic damage

Company Profile: MTR Technologies

AmBisome and DaunoXome receive additional approvals

Fujisawa outlicenses veterinary anthelmintic agent to Bayer

Astra obtains rights from Takeda to develop TxA2 antagonist

Another series of substance P antagonists discovered at Pfizer

Oral and parenteral formulations of levofloxacin now available in U.K.

KW-2170: in vitro and in vivo antitumor activity of a new pyrazoloacridone

Allelix: Q2 FY 1998 highlights

Fraxiparine now listed on Canadian health plan formularies

Cheung seeks FDA approval to begin testing of BPH treatment system

Gastric prokinetic effects and safety of EM-574 in healthy subjects

New PDE IV inhibitors for asthma reported by Celltech

Patient dosing begins in trial of Allelix's selective serotonin agonist

Meridian signs supply agreement with HGSI for cancer therapies

Cancer drug discovery alliance formed

CETP inhibitors for lipoprotein disorders discovered at Bayer

Gilead prepares orally active prodrugs of PMPA

Pipeline update from Yuhan

Nasally delivered influenza vaccine enters phase I

Low-dose oral interferon alfa: a patient-friendly treatment for chronic diseases on the horizon

hu1124 shows clinical activity in phase I for psoriasis

Fullerenol-1: a fullerene derivative for the treatment of atherosclerosis

Naturally occurring inhibitors of ICAM-1-mediated cell adhesion discovered by Taisho

Dopaminergic compound CI-1007 evaluated in schizophrenic patients

Intrathecal SNX-111 for acute postoperative pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...